{
    "root": "30a130bd-726c-2b1d-e063-6294a90a9b33",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Paroxetine",
    "value": "20250318",
    "ingredients": [
        {
            "name": "DIBASIC CALCIUM PHOSPHATE DIHYDRATE",
            "code": "O7TSZ97GEP"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A POTATO",
            "code": "5856J3G2A2"
        },
        {
            "name": "ANHYDROUS DIBASIC CALCIUM PHOSPHATE",
            "code": "L11K75P92J"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "POLYSORBATE 80",
            "code": "6OZP39ZG8H"
        },
        {
            "name": "HYPROMELLOSE 2910 (6 MPA.S)",
            "code": "0WZ8WG20P6"
        },
        {
            "name": "POLYETHYLENE GLYCOL 400",
            "code": "B697894SGQ"
        },
        {
            "name": "D&C YELLOW NO. 10",
            "code": "35SW5USQ3G"
        },
        {
            "name": "FD&C YELLOW NO. 6",
            "code": "H77VEI93A8"
        },
        {
            "name": "PAROXETINE HYDROCHLORIDE HEMIHYDRATE",
            "code": "X2ELS050D8"
        }
    ],
    "indications": "paroxetine tablets indicated adults treatment : major depressive disorder ( mdd ) obsessive compulsive disorder ( ocd ) panic disorder ( pd ) social anxiety disorder ( sad ) generalized anxiety disorder ( gad ) posttraumatic stress disorder ( ptsd )",
    "contraindications": "recommended starting maximum daily mdd , ocd , pd , ptsd : ( 2.2 ) indication starting daily dose maximum daily dose mdd 20 mg 50 mg ocd 20 mg 60 mg pd 10 mg 60 mg ptsd 20 mg 50 mg recommended starting sad gad 20 mg daily . ( 2.3 ) elderly patients , patients severe renal impairment severe hepatic impairment : starting 10 mg daily . maximum 40 mg daily . ( 2.4 ) discontinuing paroxetine tablets , reduce gradually . ( 2.6 , 5.7 )",
    "warningsAndPrecautions": "paroxetine tablets usp , 10 mg yellow colored film-coated modified capsule shaped , biconvex tablets debossed \u2018 c 55 \u2019 one side deep breakline side . ndc : 70518-2574-00 ndc : 70518-2574-01 ndc : 70518-2574-02 ndc : 70518-2574-03 ndc : 70518-2574-04 packaging : 90 1 bottle plastic packaging : 30 1 box packaging : 1 1 pouch packaging : 30 1 blister pack packaging : 90 1 bottle plastic store 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) ; excursions permitted 15\u00b0 30\u00b0c ( 59\u00b0 86\u00b0f ) [ usp controlled room temperature ] . repackaged distributed : remedy repack , inc. 625 kolter dr. suite # 4 indiana , pa 1-724-465-8762",
    "adverseReactions": "paroxetine tablets contraindicated patients : taking , within 14 days stopping , maois ( including maois linezolid intravenous methylene blue ) increased risk serotonin syndrome [ ( 5.2 ) , ( 7 ) ] . taking thioridazine risk qt prolongation [ ( 5.3 ) , ( 7 ) ] . taking pimozide risk qt prolongation [ ( 5.3 ) , ( 7 ) ] . known hypersensitivity ( e.g . , anaphylaxis , angioedema , stevens-johnson syndrome ) paroxetine inactive ingredients paroxetine tablets [ ( 6.1 ) , ( 6.2 ) ] .",
    "indications_original": "Paroxetine tablets are indicated in adults for the treatment of:\u00a0\n                  \n                     Major depressive disorder (MDD)\n                     Obsessive compulsive disorder (OCD)\n                     Panic disorder (PD)\n                     Social anxiety disorder (SAD)\n                     Generalized anxiety disorder (GAD)\n                     Posttraumatic stress disorder (PTSD)",
    "contraindications_original": "Recommended starting and maximum daily dosage for MDD, OCD, PD, and PTSD: ( 2.2 ) Indication Starting Daily Dose Maximum Daily Dose MDD 20 mg 50 mg OCD 20 mg 60 mg PD 10 mg 60 mg PTSD 20 mg 50 mg Recommended starting dosage for SAD and GAD is 20 mg daily. ( 2.3 ) Elderly patients, patients with severe renal impairment or severe hepatic impairment: Starting dosage is 10 mg daily. Maximum dosage is 40 mg daily. ( 2.4 ) When discontinuing paroxetine tablets, reduce dosage gradually. ( 2.6 , 5.7 )",
    "warningsAndPrecautions_original": "Paroxetine Tablets USP, 10 mg\u00a0are yellow colored film-coated modified capsule shaped, biconvex tablets debossed with \u2018C 55\u2019 on one side and a deep breakline on the other side.\n                  \n                  NDC: 70518-2574-00\n                  NDC: 70518-2574-01\n                  NDC: 70518-2574-02\n                  NDC: 70518-2574-03\n                  NDC: 70518-2574-04\n                  PACKAGING: 90 in 1 BOTTLE PLASTIC\n                  PACKAGING: 30 in 1 BOX\n                  PACKAGING: 1 in 1 POUCH\n                  PACKAGING: 30 in 1 BLISTER PACK\n                  PACKAGING: 90 in 1 BOTTLE PLASTIC\n                  \n                  Store at\u00a020\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F); excursions permitted to 15\u00b0 to 30\u00b0C (59\u00b0 to 86\u00b0F) [see USP Controlled Room Temperature].\n                  \n                  Repackaged and Distributed By:\n                  Remedy Repack, Inc.\n                  625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762",
    "adverseReactions_original": "Paroxetine tablets are contraindicated in patients:\n                  \n                     Taking, or within 14 days of stopping, MAOIs (including the MAOIs linezolid and intravenous methylene blue) because of an increased risk of serotonin syndrome\n  \n   [see\u00a0\n  \n   \n                           Warnings and Precautions (5.2)\n                        \n                        ,\n                        \n                           \n                              \n                                 Drug Interactions (7)\n                              ].\n   \n    \n                        \n                     \n                     Taking thioridazine because of risk of QT prolongation\n  \n   [see\u00a0\n   \n    \n                              Warnings and Precautions (5.3)\n                           ,\u00a0\n   \n    \n                              Drug Interactions (7)\n                           ].\n  \n   \n                     \n                     Taking pimozide because of risk of QT prolongation\n  \n   [see\n   \n    \n                              Warnings and Precautions (5.3)\n                           ,\n   \n    \n                              Drug Interactions (7)\n                           ].\n  \n   \u00a0\n \n  \n                     With known hypersensitivity (e.g., anaphylaxis, angioedema, Stevens-Johnson syndrome) to paroxetine or any of the inactive ingredients in paroxetine tablets\n  \n   [see\n   \n    \n                              Adverse Reactions (6.1)\n                           ,\n   \n    \n                              (6.2)\n                           ]\n  \n   ."
}